Neuroleptic Malignant Syndrome
A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
Year introduced: 1986(1985)
PubMed search builder options
Subheadings:
Tree Number(s): C10.228.140.079.737, C10.720.737, C25.723.705.600
MeSH Unique ID: D009459
Entry Terms:
- Neuroleptic Malignant Syndromes
- Syndrome, Neuroleptic Malignant
- Syndromes, Neuroleptic Malignant
- NMS (Neuroleptic Malignant Syndrome)
- NMSs (Neuroleptic Malignant Syndrome)
- Neuroleptic-Induced Neuroleptic Malignant Syndrome
- Neuroleptic Induced Neuroleptic Malignant Syndrome
- Neuroleptic-Malignant Syndrome, Neuroleptic Induced
- Neuroleptic Malignant Syndrome, Neuroleptic Induced
Previous Indexing: